Replies to post #119065 on Biotech Values

[genisi]

Bimonthly dosing (after the initial loading period) is already the de facto SoC for Lucentis in AMD, and the CATT study produced no data to change this

The ongoing HARBOR trial http://clinicaltrials.gov/ct2/show/NCT00891735 might produce the clinical data for dosing frequency (and perhaps even better efficacy for the higher dose Lucentis).